Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial

EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results

(2017) A. M. Eggermont et al.   JOURNAL OF CLINICAL ONCOLOGY

Brachytherapy: Current Status and Future Strategies — Can High Dose Rate Replace Low Dose Rate and External Beam Radiotherapy?

(2013) G.C. Morton et al.   CLINICAL ONCOLOGY

Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma

(2010) A. A. Sarnaik et al.   CLINICAL CANCER RESEARCH

Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis

(2010) S. Mocellin et al.   JNCI-Journal of the National Cancer Institute

Anti–CTLA-4 Antibody Adjuvant Therapy in Melanoma

(2010) Alexander M.M. Eggermont et al.   SEMINARS IN ONCOLOGY

Therapeutic vaccines in solid tumours: Can they be harmful?

(2009) Alexander M.M. Eggermont   EUROPEAN JOURNAL OF CANCER

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY